Biomaterials company licenses absorbable hemostat product - Philadelphia Business Journal:

http://nekretnine-hr.net/en/pretraga-nekretnina-na-mapi-hrvatske
The purchase is part of Orthovita's strategy to expand its producf line to better leverage its biomaterialssales force. Financialo terms of the deal with a medical-device company in were not disclosed. The agreement expires in 2013, but Orthovitza has the right to renew the agreement for anadditionakl three-year period if the company meetse undisclosed purchase obligations during the fifth year of the agreement. Orthovita plans to rebrandc the product, approved by the Food and Drug Administration in as Vitasureabsorbable hemostat. Hemostate are used to prevent bleedinduring surgery.
Antony Koblish, the presidentr and CEO of Orthovita, described VitaSure as an cost-effective hemostat" that requires no mixing, reconstitutio or preparation assembly and can be used throughoutf asurgical procedure. He said it will complement the company'zs existing Vitagel surgical hemostat product, which is used primarilty at the end of a surgical procedure to stop Orthovita expects to launch Vitasure by the thirdc quarter of the year domestically and in 2009 in the territoriesw outside of theUnited States.
The compant earlier this year launched its Vitoss bioactive foam bone graft substitutes product in the orthopedic surgery The Drug Information Association has opened an officesin Mumbia, India, in response to the growing biopharmaceutica l industry in that country. India's biopharmaceutical which generated revenue of morethan $100 million in 2006, is expectede to reach the $1 billion mark by 2010. "The statisticz are incredible," said Linda McGoldrick, DIA'zs worldwide executive director. "More than 15 percent of the world'w clinical trials are expected to be conducted in Indiasby 2011." DIA of Horsham also has officed in Basel, Switzerland, and Tokyo.
The company organizew domestic andinternational meetings, training courses, workshops and webinarsz designed to help biotechnology and pharmaceutical companies advance their drug discovery and developmenf efforts. "We bring together industry, academia, regulators and patienyt organizations to provide ongoing trainingt for professionals on clinical practices and safety standards that will impact the approvalk of drugs developed in India for theglobal market," McGoldrick said. The Europeab Commission granted orphan drug statusto 's experimental ovarianb cancer treatment drug, Morab-003, and its experimentalk pancreatic cancer treatment Morab-009.
The designation would provide the two monoclonal antibodieas with 10 years of market exclusivity in the EU if the drugdsare approved. Both new drug candidates are in midstagsclinical testing. Morphotek of Exton is a subsidiary ofEisai Co. Ltd. of Japaj ... Zelos Therapeutics in West Conshohocke has entered into a collaboration agreement with Aegis Therapeutics of San Diego under whicuh the two will work together to develop an intranasal spray formulationof ZT-031, Zelos' experimental treatmenr for osteoporosis and other bone The company expects to begin phase-III studies, the last step before seeking product approval, for ZT-031 latert this year ...
of Huntingdon Valley receivee a four-year grant from the Netherlands-based Centerd for Translational Molecular Medicine to developp a test to detect minimal residual disease in the bloo of acute myeloid leukemia Terms of the grant werenot disclosed.